GB201603291D0 - Antibodies - Google Patents

Antibodies

Info

Publication number
GB201603291D0
GB201603291D0 GBGB1603291.4A GB201603291A GB201603291D0 GB 201603291 D0 GB201603291 D0 GB 201603291D0 GB 201603291 A GB201603291 A GB 201603291A GB 201603291 D0 GB201603291 D0 GB 201603291D0
Authority
GB
United Kingdom
Prior art keywords
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1603291.4A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Binding Site Group Ltd
Original Assignee
Binding Site Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55806928&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB201603291(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Binding Site Group Ltd filed Critical Binding Site Group Ltd
Priority to GBGB1603291.4A priority Critical patent/GB201603291D0/en
Publication of GB201603291D0 publication Critical patent/GB201603291D0/en
Priority to EP17708320.1A priority patent/EP3420361B1/en
Priority to KR1020187027703A priority patent/KR102851057B1/ko
Priority to ES17708320T priority patent/ES2936783T3/es
Priority to BR112018067435-4A priority patent/BR112018067435B1/pt
Priority to PCT/GB2017/050489 priority patent/WO2017144900A1/en
Priority to DK17708320.1T priority patent/DK3420361T3/da
Priority to JP2018544901A priority patent/JP7246927B2/ja
Priority to AU2017222399A priority patent/AU2017222399B2/en
Priority to CA3015296A priority patent/CA3015296C/en
Priority to PCT/GB2017/050492 priority patent/WO2017144903A1/en
Priority to AU2017222402A priority patent/AU2017222402B2/en
Priority to EP17708323.5A priority patent/EP3420362B1/en
Priority to US16/079,165 priority patent/US20190048064A1/en
Priority to CN202211574983.0A priority patent/CN116148479A/zh
Priority to CN201780013491.5A priority patent/CN108885218A/zh
Priority to EP22190012.9A priority patent/EP4123308A1/en
Priority to US16/078,986 priority patent/US12461108B2/en
Priority to ES17708323T priority patent/ES2942315T3/es
Priority to JP2022017497A priority patent/JP7541045B2/ja
Priority to JP2022198753A priority patent/JP7541070B2/ja
Priority to US18/454,967 priority patent/US20230391851A1/en
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00Sampling; Preparing specimens for investigation
    • G01N1/28Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/34Purifying; Cleaning
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/62Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosols; by investigating electric discharges, e.g. emission of cathode
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848Methods of protein analysis involving mass spectrometry
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54F(ab')2
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00Chemical aspects of mass spectrometric analysis of biological material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/24Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Electrochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Sampling And Sample Adjustment (AREA)
GBGB1603291.4A 2016-02-25 2016-02-25 Antibodies Ceased GB201603291D0 (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
GBGB1603291.4A GB201603291D0 (en) 2016-02-25 2016-02-25 Antibodies
US16/078,986 US12461108B2 (en) 2016-02-25 2017-02-24 Mass spectrometry kit including a cross-linked antibody or fragment thereof
ES17708323T ES2942315T3 (es) 2016-02-25 2017-02-24 Anticuerpos
CA3015296A CA3015296C (en) 2016-02-25 2017-02-24 Mass spectrometry kit
EP17708323.5A EP3420362B1 (en) 2016-02-25 2017-02-24 Antibodies
ES17708320T ES2936783T3 (es) 2016-02-25 2017-02-24 Kit de espectrometría de masas
BR112018067435-4A BR112018067435B1 (pt) 2016-02-25 2017-02-24 Método para purificar ou caracterizar uma imunoglobulina, método para quantificar uma quantidade de um analito de indivíduo ou um fragmento de um analito em uma amostra do indivíduo, método de preparação de uma amostra para análise de espectrometria de massa, método para diagnosticar ou prognosticar uma doença relacionada a células b ou outra doença relacionada com a imunidade, e kits de ensaio
PCT/GB2017/050489 WO2017144900A1 (en) 2016-02-25 2017-02-24 Mass spectrometry kit
DK17708320.1T DK3420361T3 (da) 2016-02-25 2017-02-24 Massespektrometrikit
JP2018544901A JP7246927B2 (ja) 2016-02-25 2017-02-24 質量分析キット
AU2017222399A AU2017222399B2 (en) 2016-02-25 2017-02-24 Mass spectrometry kit
EP17708320.1A EP3420361B1 (en) 2016-02-25 2017-02-24 Mass spectrometry kit
PCT/GB2017/050492 WO2017144903A1 (en) 2016-02-25 2017-02-24 Antibodies
AU2017222402A AU2017222402B2 (en) 2016-02-25 2017-02-24 Antibodies
KR1020187027703A KR102851057B1 (ko) 2016-02-25 2017-02-24 질량 분석 키트
US16/079,165 US20190048064A1 (en) 2016-02-25 2017-02-24 Antibodies
CN202211574983.0A CN116148479A (zh) 2016-02-25 2017-02-24 质谱法试剂盒
CN201780013491.5A CN108885218A (zh) 2016-02-25 2017-02-24 质谱法试剂盒
EP22190012.9A EP4123308A1 (en) 2016-02-25 2017-02-24 Mass spectrometry kit
JP2022017497A JP7541045B2 (ja) 2016-02-25 2022-02-07 質量分析キット
JP2022198753A JP7541070B2 (ja) 2016-02-25 2022-12-13 質量分析キット
US18/454,967 US20230391851A1 (en) 2016-02-25 2023-08-24 Antibodies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1603291.4A GB201603291D0 (en) 2016-02-25 2016-02-25 Antibodies

Publications (1)

Publication Number Publication Date
GB201603291D0 true GB201603291D0 (en) 2016-04-13

Family

ID=55806928

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1603291.4A Ceased GB201603291D0 (en) 2016-02-25 2016-02-25 Antibodies

Country Status (10)

Country Link
US (1) US12461108B2 (https=)
EP (2) EP4123308A1 (https=)
JP (3) JP7246927B2 (https=)
KR (1) KR102851057B1 (https=)
CN (2) CN116148479A (https=)
AU (1) AU2017222399B2 (https=)
DK (1) DK3420361T3 (https=)
ES (1) ES2936783T3 (https=)
GB (1) GB201603291D0 (https=)
WO (1) WO2017144900A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201708262D0 (en) 2017-05-23 2017-07-05 Binding Site Group Ltd Assay for plasma cell associated disease
CA3126712A1 (en) * 2019-01-31 2020-08-06 Regeneron Pharmaceuticals, Inc. Native microfluidic ce-ms analysis of antibody charge heterogeneity
CN110009008B (zh) * 2019-03-18 2020-11-06 四川大学 基于提取的免疫固定电泳图特征对其进行自动分类的方法
GB201906599D0 (en) 2019-05-10 2019-06-26 Binding Site Group Ltd Mass spectrometry calibrator
WO2020229794A1 (en) 2019-05-10 2020-11-19 The Binding Site Group Limited Mass spectrometry calibrator
GB201915946D0 (en) 2019-11-01 2019-12-18 Binding Site Group Ltd Quantitation of immunoglobulins i n mass spectrometry
GB202007047D0 (en) * 2020-05-13 2020-06-24 Binding Site Group Ltd Mass spectrometry controls
GB202008887D0 (en) * 2020-06-11 2020-07-29 Binding Site Group Ltd A method of identifying or characterising an immune response in a subject
GB202016822D0 (en) 2020-10-23 2020-12-09 Binding Site Group Ltd Quantitation of immunoglobulins in mass spectrometry
CN113720900A (zh) * 2021-09-14 2021-11-30 首都医科大学附属北京朝阳医院 一种基于madli-tof ms技术检测血清中m蛋白的方法
CN114324557B (zh) * 2021-12-03 2024-05-10 融智生物科技(青岛)有限公司 一种基于MALDI-TOF MS的ζ-珠蛋白的检测方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6290090A (en) 1989-08-29 1991-04-08 University Of Southampton Bi-or trispecific (fab)3 or (fab)4 conjugates
WO1991006570A1 (en) * 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
EP1400536A1 (en) * 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
ES2242189T3 (es) * 1994-05-13 2005-11-01 Miltenyi Biotec Gmbh Columna esteril y apirogena copulada a una proteina con miras a la fijacion y extraccion de sustancias dadas de la sangre.
JP2826965B2 (ja) * 1995-01-12 1998-11-18 オリエンタル酵母工業株式会社 免疫吸着体とその製造法
EP0862584B1 (en) 1995-11-03 2004-12-22 The Binding Site Limited Production of antibodies
US6207370B1 (en) * 1997-09-02 2001-03-27 Sequenom, Inc. Diagnostics based on mass spectrometric detection of translated target polypeptides
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
WO2005035721A2 (en) * 2003-10-08 2005-04-21 Ebioscience Native immunoglobulin binding reagents and methods for making and using same
GB0501741D0 (en) * 2005-01-27 2005-03-02 Binding Site The Ltd Antibody
CA2600844A1 (en) * 2005-03-14 2006-09-21 Medimmune, Inc. Macromolecules comprising a thioether cross-link
US7781178B2 (en) 2005-04-12 2010-08-24 Akira Matsumori Biomarker for diagnosing heart disease and the use thereof
US7893616B2 (en) * 2006-02-27 2011-02-22 Ohio State University Process to determine enzyme activity
US20100015652A1 (en) 2006-12-21 2010-01-21 Brian Walter Granda Antibody quantitation
RU2012118620A (ru) 2009-10-09 2013-11-20 Симфоген А/С Множественное количественное определение в смеси индивидуальных рекомбинантных белков посредством сигнатурных пептидов и масс-спектрометрии
GB201001946D0 (en) 2010-02-05 2010-03-24 Binding Site Group The Ltd Cancer prognostic assay
GB2478520A (en) 2010-03-02 2011-09-14 Binding Site Group Ltd Kidney prognostic assay
GB201117172D0 (en) 2011-10-05 2011-11-16 Binding Site Group The Ltd Diabetes
GB201121265D0 (en) 2011-12-12 2012-01-18 Binding Site Group The Ltd Assay
JP2015510877A (ja) * 2012-03-09 2015-04-13 ユーシーエル ビジネス パブリック リミテッド カンパニー 抗体の化学修飾
WO2014121031A1 (en) 2013-01-31 2014-08-07 Excelimmune, Inc. Characterization of antibody mixtures by mass spectrometry
WO2015131169A2 (en) * 2014-02-28 2015-09-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. Personalized myeloma detection
WO2015154052A1 (en) 2014-04-04 2015-10-08 Mayo Foundation For Medical Education And Research Isotyping immunoglobulins using accurate molecular mass
EP3175242A4 (en) * 2014-07-29 2017-12-27 Mayo Foundation for Medical Education and Research Quantifying monoclonal antibody therapeutics by lc-ms/ms
PT3209767T (pt) * 2014-10-21 2020-11-09 Gennova Biopharmaceuticals Ltd Um novo processo de purificação para isolamento e produção comercial de tnk-tpa recombinante (tenecteplase)
CN108026164A (zh) 2015-09-24 2018-05-11 梅约医学教育与研究基金会 通过质谱鉴定免疫球蛋白游离轻链
GB201708262D0 (en) * 2017-05-23 2017-07-05 Binding Site Group Ltd Assay for plasma cell associated disease

Also Published As

Publication number Publication date
EP3420361B1 (en) 2023-01-04
JP2022069446A (ja) 2022-05-11
KR102851057B1 (ko) 2025-08-28
KR20180132651A (ko) 2018-12-12
JP7541070B2 (ja) 2024-08-27
EP4123308A1 (en) 2023-01-25
CA3015296A1 (en) 2017-08-31
WO2017144900A1 (en) 2017-08-31
CN116148479A (zh) 2023-05-23
ES2936783T3 (es) 2023-03-22
DK3420361T3 (da) 2023-01-23
EP3420361A1 (en) 2019-01-02
US20190094239A1 (en) 2019-03-28
AU2017222399B2 (en) 2024-03-14
AU2017222399A1 (en) 2018-08-30
US12461108B2 (en) 2025-11-04
CN108885218A (zh) 2018-11-23
JP7541045B2 (ja) 2024-08-27
BR112018067435A2 (pt) 2019-01-02
JP7246927B2 (ja) 2023-03-28
JP2023033281A (ja) 2023-03-10
JP2019509483A (ja) 2019-04-04

Similar Documents

Publication Publication Date Title
ZA201900373B (en) Anti-tim-3 antibodies
IL259048A (en) Antibodies against ror-1
SG10201601719RA (en) Anti-LAG-3 Antibodies
GB201601073D0 (en) Antibodies
SG10201913864RA (en) Anti-LAG-3 Antibodies
GB201621439D0 (en) IL-11Ra Antibodies
IL253633A0 (en) Anti-transthyretin antibodies
GB201521393D0 (en) Antibodies
GB201610044D0 (en) Antibodies
GB201521391D0 (en) Antibodies
PL3250593T3 (pl) Przeciwciała przeciwko transtyretynie
SG10202010735PA (en) Tau-binding antibodies
GB201521382D0 (en) Antibodies
IL255323A0 (en) Anti-fcrn antibodies
GB201616699D0 (en) Antibodies
ZA201808317B (en) Anti-tnfrsf25 antibodies
GB201603291D0 (en) Antibodies
PT3484921T (pt) Anticorpos anti-il-22r
IL260083B1 (en) Antibody against myl9
GB201509907D0 (en) Antibodies
GB201503438D0 (en) Antibodies
GB201522394D0 (en) Antibodies
IL284022A (en) Anti-transthyretin antibodies
GB201622197D0 (en) Antibodies
GB201620414D0 (en) Antibodies

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)